4.9 (371) In stock
In a phase II clinical trial, 29 patients with metastatic castration-resistant prostate cancer were treated with ipilimumab after tumor resection. Median radiographic PFS was 3 months, median clinical PFS was 2 months, and median OS was 24 months. Best ORR was stable disease in 37% of patients. In the “favorable” cohort (PFS>6 months, median OS of 45 months), pretreatment tumors had increased CD8+ T cell density and IFNγ response gene signature compared with the “unfavorable” cohort (PFS<6 months, median OS of 5 months), while TMB was similar between cohorts. In post-treatment PBMCs, CD8+ T cell responses to PSMA, PAP, and/or neoantigens were found in 4 patients, all of which were in the favorable cohort.
Frontiers The good and the bad of T cell cross-reactivity: challenges and opportunities for novel therapeutics in autoimmunity and cancer
Manufacturing Personalised Cancer Vaccines
The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells, Molecular Cancer
Unleashing the power of DNA: fighting cancer with tailored vaccines
How do cancer vaccines work?
When neoantigen expression is low, the T cells won't go
Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges, Biomarker Research
Research Suggests How Boosting Neoantigens Can Make Immunotherapy More Effective
Cancers, Free Full-Text
A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers - ScienceDirect
Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges, Biomarker Research
Overcoming tumor antigen heterogeneity in
What is T cell therapy?
